Paper 21 Entered: March 8, 2018

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., Petitioner

v.

POZEN INC. and HORIZON PHARMA USA, INC., Patent Owners.

> Case IPR2017-01995 Patent 9,220,689 B2

Before TONI R. SCHEINER, MICHELLE N. ANKENBRAND, and DEBRA L. DENNETT, *Administrative Patent Judges*.

DENNETT, Administrative Patent Judge.

ORDER

Granting Patent Owner Horizon Pharma USA, Inc.'s Motion for *Pro Hac Vice* Admission of Susan Krumplitsch 37 C.F.R. § 42.10

Patent Owner Horizon Pharma USA, Inc. ("Horizon") filed a Motion for

Admission Pro Hac Vice of Susan Krumplitsch under 37 C.F.R. § 42.10(c).

Paper 13. The Motion is supported by the Declaration of Ms. Krumplitsch.

Ex. 2009. Horizon represents that Petitioner does not oppose grant of this motion.

The Board has reviewed the submissions and determined that the requirements of 37 C.F.R. § 42.10 have been met and there is good cause to admit Ms. Krumplitsch *pro hac vice* in the proceeding.

It is, therefore,

ORDERED that Horizon's Motion for Admission *Pro Hac Vice* of Susan Krumplitsch under 37 C.F.R. § 42.10 is granted;

FURTHER ORDERED that Ms. Krumplitsch is authorized to represent Horizon as back-up counsel only, and that Horizon is to continue to have a registered practitioner represent it as lead counsel;

FURTHER ORDERED that Ms. Krumplitsch shall comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials, as set forth in Part 42 of 37 C.F.R.; and

FURTHER ORDERED that Ms. Krumplitsch shall be subject to the Office's disciplinary jurisdiction under 37 C.F.R. § 11.19(a) and the Office's Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101–11.901.

PETITIONER:

Brandon M. White Emily Greb PERKINS COIE LLP bmwhite@perkinscoie.com egreb@perkinscoie.com

PATENT OWNER:

Thomas A. Blinka, Ph.D. COOLEY LLP TBlinka@cooley.com

Margaret J. Sampson, Ph.D. BAKER BOTTS LLP Margaret.Sampson@bakerbotts.com